Disc Medicine CEO sells 33,000 shares under plan

Disc Medicine, Inc. Chief Executive Officer and director John D. Quisel reported option-related trades on July 13, 2026.

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Executive Officer and director John D. Quisel reported option-related trades on July 13, 2026. He exercised stock options for 33,000 shares of common stock at strike prices of $13.50 and $9.86, and sold 33,000 shares in open-market transactions at weighted-average prices of $76.0520, $74.9469 and $74.2729, with individual trades ranging from $73.62 to $76.29. These sales were made under a Rule 10b5-1 trading plan adopted on March 12, 2026. Following the transactions, he holds 226,064 common shares directly and retains stock options covering 124,586 and 15,791 underlying shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 33,000 shares ($2.12M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Quisel John D

Role Chief Executive Officer

Sold 33,000 shs ($2.47M)

Approx. gross sale proceeds $2.47M

Approx. exercise cost $352K

Approx. pre-tax spread $2.12M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F5	25,584	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F1, F6	7,416	$0.00	$0.00
Exercise	Common Stock F1	25,584	$9.86	$252K
Exercise	Common Stock F1	7,416	$13.50	$100K
Sale	Common Stock F1, F2	9,704	$74.2729	$721K
Sale	Common Stock F1, F3	16,896	$74.9469	$1.27M
Sale	Common Stock F1, F4	6,400	$76.052	$487K

Holdings After Transaction: Stock Option (Right to Buy) — 140,377 contracts (Direct); Common Stock — 226,064 shares (Direct)

Footnotes (6)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.62 to $75.50, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.83 to $76.29, inclusive.
5. F5. The shares underlying this option are fully vested and exercisable as of the date hereof.
6. F6. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 33,000 shares Sale price tranche 1: $76.0520 per share Sale price tranche 2: $74.9469 per share +5 more

8 metrics

Shares sold 33,000 shares Common stock sold in open-market transactions on July 13, 2026

Sale price tranche 1 $76.0520 per share Weighted-average price for 6,400-share sale tranche

Sale price tranche 2 $74.9469 per share Weighted-average price for 16,896-share sale tranche

Sale price tranche 3 $74.2729 per share Weighted-average price for 9,704-share sale tranche

Shares acquired via option exercise 33,000 shares Common stock obtained by exercising options on July 13, 2026

Option exercise price 1 $13.50 per share Strike price for 7,416-share stock option grant expiring December 28, 2032

Option exercise price 2 $9.86 per share Strike price for 25,584-share stock option grant expiring September 13, 2031

Common shares held after transactions 226,064 shares Direct ownership of Disc Medicine common stock following reported trades

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected ... pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vest in 48 equal monthly installments financial

"shares underlying this option vest in 48 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Disc Medicine (IRON) CEO John D. Quisel report?

John D. Quisel reported exercising options for 33,000 shares and selling 33,000 shares of Disc Medicine common stock on July 13, 2026. The trades reflect option exercises at $13.50 and $9.86 per share and open-market sales executed the same day.

How many Disc Medicine (IRON) shares did the CEO sell and at what prices?

He sold a total of 33,000 shares in three open-market tranches at weighted-average prices of $76.0520, $74.9469 and $74.2729. According to footnotes, individual trade prices ranged from $73.62 to $76.29 per share across the transactions.

What stock options did the Disc Medicine (IRON) CEO exercise in this Form 4?

He exercised options for 7,416 shares at $13.50 and 25,584 shares at $9.86 per share. The $13.50 grant is fully vested, while the $9.86 grant vests in 48 equal monthly installments following December 29, 2022, subject to continued service.

How many Disc Medicine (IRON) shares and options does the CEO hold after these transactions?

After the reported trades, John D. Quisel directly holds 226,064 Disc Medicine common shares. He also retains stock options labeled “Stock Option (Right to Buy)” covering 124,586 and 15,791 underlying shares, according to the post-transaction derivative holdings reported.

Were the Disc Medicine (IRON) CEO share sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. Such plans pre-arrange trades, reducing the significance of day-to-day timing decisions by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 06:32 PM Accepted by SEC EDGAR 07/14/2026 - 06:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quisel John D

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/13/2026		M(1)		25,584	A	$9.86	251,648	D
Common Stock	07/13/2026		M(1)		7,416	A	$13.5	259,064	D
Common Stock	07/13/2026		S(1)		9,704	D	$74.2729(2)	249,360	D
Common Stock	07/13/2026		S(1)		16,896	D	$74.9469(3)	232,464	D
Common Stock	07/13/2026		S(1)		6,400	D	$76.052(4)	226,064	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.86	07/13/2026		M(1)			25,584	(5)	09/13/2031	Common Stock	25,584	$0	15,791	D
Stock Option (Right to Buy)	$13.5	07/13/2026		M(1)			7,416	(6)	12/28/2032	Common Stock	7,416	$0	124,586	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.62 to $75.50, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.83 to $76.29, inclusive.

5. The shares underlying this option are fully vested and exercisable as of the date hereof.

6. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)